1 / 26

Pharmacoepidemiology: Goals and Methods

CCEB. Pharmacoepidemiology: Goals and Methods. Sean Hennessy, PharmD, PhD Assistant Professor of Epidemiology & Pharmacology Center for Clinical Epidemiology and Biostatistics University of Pennsylvania School of Medicine.

stinson
Télécharger la présentation

Pharmacoepidemiology: Goals and Methods

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CCEB Pharmacoepidemiology: Goals and Methods Sean Hennessy, PharmD, PhD Assistant Professor of Epidemiology & Pharmacology Center for Clinical Epidemiology and Biostatistics University of Pennsylvania School of Medicine

  2. “The study of the use and effects of medications in large numbers of people” Strom

  3. “The application of epidemiologic knowledge, methods, and reasoning to the study of the effects (beneficial and adverse) and use of drugs in human populations.” Porta and Hartzema

  4. “The study of drugs as determinants of health and disease in the general unselected population.” Spitzer

  5. Clinical pharmacology Pharmacoepidemiology Epidemiology Strom

  6. Pharmacology Therapeutics Pharmacoepidemiology Epidemiology Statistics Spitzer

  7. Health services research Economics Epidemiology Health economics Outcomes research Clinical epidemiology Pharmaco- Epidemiology Conceptualization by Harry Guess

  8. Animal studies Phase 1 Phase 2 Human subjects Phase 3 Drug approval • Not always required Phase 4 • Human subjects

  9. Pre-marketing Post-marketing Pre-de-marketing

  10. Limitations of Pre-marketing Trials-1 • Carefully selected subjects may not reflect real-life patients in whom drug will be used • Study subjects may receive better care than real-life patients • Short duration of treatment

  11. Limitations of pre-marketing trials-2 • Study size • Studies with 3000 patients cannot reliably detect adverse events with an incidence of < 1 per 1000, even if severe • Studies with 500 patients cannot reliably detect adverse events with an incidence of < 1 per 166, even if severe

  12. Consequences of Limitations of Pre-marketing Trials • About 20% of drugs get new “black box” warnings after marketing • About 4% of drugs are ultimately withdrawn for safety reasons

  13. Hypothesis generating Hypothesis strengthening Hypothesis testing

  14. Case Reports & Case Series Cerivastatin (Baycol), an effective and inexpensive lipid lowering drug, was introduced in 1997. It was removed from the market in 2001 because of reports of fatal cases muscle breakdown (rhabdomyolysis).

  15. Ecologic studies Obtain group-level exposure information and disease prevalence at the same point in time.

  16. Ecologic Studies: Breast Cancer Incidence by National Fat Intake USA Switzerland Italy UK Israel N Zealand Sweden France Yugoslavia Spain Romania Poland Hong Kong Hungary Japan

  17. Randomized Trial Treated Random process Untreated Observation Period Study population = Study outcome

  18. Rate Ratio = Events / person-time in exposed Events / person-time in unexposed

  19. Cohort study Treated Non-Random process Untreated Observation Period Study population = Study outcome

  20. Rate Ratio = Events / person-time in exposed Events / person-time in unexposed A RCT is just a special case of a cohort study

  21. Case-control study* Controls sampled Treated Non-Random process Untreated Observation Period Study population = Study outcome (*using “risk-set sampling”)

  22. Cohort vs. Case-Control • Advantages of cohort studies -Can calculate incidence -Can directly calculate relative risk -Less measurement error? -Can study multiple outcomes of single exposure • Advantages of case-control studies -Need exposure and confounder info on fewer subjects -Often quicker, less expensive -Can study multiple causes of a single disease

  23. Data sources • Spontaneous reporting systems • Ad-hoc studies • Health Care data • Medicaid • General Practice Research Database • Tayside Medicines Monitoring Unit • Group Health Cooperative of Puget Sound • United Health • Etc.

More Related